deltatrials
Terminated PHASE2 INTERVENTIONAL 5-arm NCT04363801

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (DisTinGuish)

A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)

Sponsor: BeiGene

Conditions Gastric Adenocarcinoma Gastric Cancer GastroEsophageal Cancer
Interventions Capecitabine 1000mg/ m2 twice daily (BID) DKN-01 300mg DKN-01 400mg DKN-01 600mg Fluorouracil Leucovorin Calcium Oxaliplatin Tislelizumab 200mg Tislelizumab 400mg
Updated 19 times since 2020 Last updated: Sep 22, 2025 Started: Jul 29, 2020 Primary completion: Mar 31, 2025 Completion: Mar 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

experimental treatment will not be more efficacious than its comparator in the primary endpoint of PFS

Other terminated trials from BeiGene

See all terminations from BeiGene

A PHASE2 clinical study on Gastric Adenocarcinoma and Gastric Cancer, this trial is terminated or withdrawn. The trial is conducted by BeiGene and has accumulated 19 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2020 – ~Sep 2020 · 4 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2022 · 13 months · monthly snapshot~May 2022 – ~Feb 2023 · 9 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Feb 2024 · 4 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

19 versions recorded

  1. Nov 2025 — Present [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Sep 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 14 earlier versions

  1. Oct 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

  2. Aug 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  3. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  4. May 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  5. Mar 2023 — May 2023 [monthly]

    Recruiting PHASE2

  6. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  7. May 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  8. Apr 2021 — May 2022 [monthly]

    Recruiting PHASE2

  9. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  10. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  11. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  12. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  13. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  14. May 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeiGene
  • Leap Therapeutics, Inc.
Data source: Leap Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ansan-si, South Korea , Anyang, South Korea , Berlin, Germany , Boston, United States , Busan, South Korea , Chicago, United States , Covington, United States , Duarte, United States , Durham, United States , Frankfurt, Germany and 24 more locations